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Abstract  
 
 
Purpose of the review – The advent of combination therapy to provide LDL lowering 
beyond that achieved with statins necessitates the development of greater 
understanding of how drugs work together, what changes occur in key lipoprotein 
fractions, and what residual risk remains. 
Recent findings – Clinical trials of agents that, when added to statins, generate 
profound LDL lowering have been successful in reducing further the risk of 
cardiovascular disease. LDL cholesterol can be now decreased to unprecedented 
levels, so the focus of attention then shifts to other apolipoprotein B–containing, 
atherogenic lipoprotein classes such as Lipoprotein (a) and remnants of the 
metabolism of triglyceride-rich particles. ‘Non-HDL cholesterol’ is used increasingly 
(especially if measured in the non-fasting state) as a more comprehensive index of 
risk.  
Summary – Metabolic studies reveal how current drugs act in combination to achieve 
profound lipid lowering. However, care is needed in interpreting achieved LDLc and 
Non-HDLc levels in the emerging treatment paradigm.  
  
 
Introduction 
 
 
Cholesterol in the bloodstream is transported in lipoproteins that can be divided broadly 
according to structure and function into apoB-containing particles and apoA-containing 
particles. The former lipoprotein class which includes LDL -the most abundant cholesterol 
transporter in healthy individuals - is linked to increased risk of atherosclerosis and CHD (1-
4*) and there is abundant evidence to support the causal nature of this relationship (3**). 
The latter – HDL - present an enigma; this fraction exhibits many cardio-protective features, 
is strongly, inversely associated with risk of CHD (5*), but trials in which it is increased 
through pharmacological modulation have not shown clinical benefit (5,6). Current 
management strategies for prevention of cardiovascular disease, therefore, focus primarily 
on reducing levels of apoB-containing lipoproteins in the circulation (1,2). 
 
Evidence from epidemiology, pathology, genetics, and clinical outcome trials provides a 
coherent picture of LDL as a, if not ‘the’, causative factor in atherogenesis. The association of 
LDL cholesterol (LDLc) with CHD incidence is continuous, log-linear and appears to have no 
‘floor’ i.e. a lower limit below which further reduction does not lead to decreased risk of CHD 
(3, 7). This is in distinction to blood pressure, a comparable, prevalent risk factor in the 
population that needs to be maintained within an optimal, physiological range. The HOPE-3 
trial demonstrated clearly that LDLc lowering but not blood pressure lowering resulted in 
risk reduction even when subjects had average levels of these factors (8). Further support 
for this concept came from the FOURIER study which showed that addition of a proprotein 
convertase: subtilisin kexin 9 (PCSK9) inhibitor (evolocumab) to statin therapy to reduce 
LDLc to very low levels led to a proportionate decrement in CHD risk (9**,10**). 
 
LDL is the end product of a metabolic cascade in which triglyceride-rich very low density 
lipoprotein (VLDL) is progressively delipidated through the action of lipases. In some people 
this is extremely efficient, whereas in others – those with elevated plasma triglyceride levels 
-  delipidation is slower and the prolonged residence time of VLDL particles allows them to 
accumulate cholesteryl ester by transfer from other lipoproteins via the agency of 
cholesteryl ester transfer protein (CETP), and ‘remnant’ lipoprotein species are formed 
(11,12). In a similar fashion, lipolysis of chylomicrons released from the intestine in 
response to a diet fat load leads to the formation of cholesterol-rich, more slowly 
metabolized remnants. Particles from both sources are believed to be atherogenic since they 
contain apoB (VLDL remnants have apoB100, and chylomicron remnants apoB48, as the 
major structural protein), a cholesterol ‘payload’, and can permeate the arterial wall sub-
endothelial space where lesion formation is initiated (11,12). There is increasing evidence 
that the plasma concentration of remnants is related to CHD risk independent of LDLc level 
(4, 11-14).  
 
Lipoprotein (a) (Lp(a)) is a separate apoB100-containing lipoprotein class with a metabolic 
origin and fate distinct from that of the VLDL-LDL delipidation pathway (15). Genetic studies 
have reinforced the conviction that Lp(a) is a causal risk factor for CHD and therefore a 
worthwhile therapeutic target (16,17*). There has been controversy over the quantitative 
nature of the association of plasma Lp(a) with risk but recent comprehensive evaluations 
indicate that a rise of 100mg/dl in its concentration (measured as total lipoprotein mass) 
gives a risk approximately equivalent to an increase of 1.0 mmol/l (39mg/dl) in LDLc 
(17,18). 
 
The LDLc fraction as routinely assayed in the laboratory (see below for a more detailed 
discussion on methodology) incorporates LDL particles of varying size and composition, 
intermediate density lipoprotein (IDL), and Lp(a) (Figure 1). Non-HDL cholesterol (Non-
HDLc) calculated as the difference between total and HDL cholesterol is increasingly 
favoured as a measure of the entire atherogenic potential of plasma lipoproteins. It includes 
in addition to the LDL fraction, the cholesterol present in VLDL/remnant lipoproteins. Since, 
as noted above, all of these apoB containing species can contribute potentially to formation 
of atherosclerotic lesions, they are suitable targets for therapeutic invention with diet and 
drugs, and it may be that until all these particles are reduced to acceptable (minimal?) levels 
then lipoprotein-associated CHD risk will not be adequately controlled. 
 
 
Action of lipid lowering drugs on LDL- and Non-HDL cholesterol. 
 
Kinetic studies such as those depicted in Figure 1 have been undertaken in an effort 
to understand the regulatory mechanisms that control the abundance of VLDL, VLDL 
remnants, IDL and LDL in the bloodstream, and the actions of lipid-modifying drugs 
(19, 20). Achieved LDLc and Non-HDLc levels are determined by individual 
responses to agents administered as monotherapy or in combination. Evidence from 
studies so far supports the general concept that the effects of commonly used drugs 
on lipoprotein metabolism are additive (the net effect is the sum of individual 
actions) in distinction to being synergistic, or offsetting (that is, addition of a second 
agent interferes with or cancels the action of the first). 
 
Metabolic investigations have revealed that statins, ezetimibe and PCSK9 inhibitors 
share a common mechanism for lowering the levels of LDL and other apoB-
containing lipoproteins, namely increased activity of the LDL receptor. It has been 
known for many years that inhibition of cholesterol synthesis with statins, 
particularly in the liver, leads to a fall in regulatory cholesterol pools and increased 
transcription of LDL receptors. This in turn promotes uptake of LDL particles by cells 
to replenish the depleted intracellular cholesterol (Figure 1). Ezetimibe has its 
primary effect in the intestine where it blocks uptake of luminal cholesterol by 
enterocytes (21). It is believed that this leads to decreased transport of the sterol to 
liver in the chylomicron pathway and consequently a fall in hepatic cholesterol and a 
rise in receptor activity. Up-regulation of LDL clearance appears to be the main 
mechanism by which ezetimibe reduces LDLc (22). 
 
The LDL receptor is not the only gene product influenced by pharmacologically 
induced changes in intracellular cholesterol; expression of the gene coding for 
PCSK9 is also increased during statin administration (23). This protein appears to 
have both intra- and extra-cellular functions related to lipoprotein metabolism 
(23,24). The major action of circulating PCSK9 is to bind to LDL receptors and 
promote degradation, thereby decreasing their abundance on the cell surface and 
causing a reduction in LDL particle clearance rate (23-26). This pathway is 
quantitatively important; it can be calculated that in normal subjects about half of 
potential LDL receptor activity is blunted by the action of PCSK9 (25-27). The 
existence of a counter-regulatory mechanism whereby the statin-induced rise in 
PCSK9 partially offsets the stimulation of LDL receptor activity provides a 
satisfactory explanation as to why LDLc is lowered only modestly (by about a further 
6%) as the dose of statin is increased (doubled) (28).  
 
As shown in Figure 1 (based on investigations reported in 25**,26**), statin 
treatment in normolipemic volunteers caused substantial falls in IDL and LDL apoB 
pool sizes, and a modest decrement in VLDL apoB, due to increased clearance of 
these lipoprotein classes. A qualitatively and quantitatively similar effect was 
observed when a PCSK9 inhibitor was given as monotherapy (25,26). Subjects 
treated with statin plus PCSK9 inhibitor demonstrated a profound reduction in LDL 
apoB pool size (Figure 1) - to 15% of the off-treatment value– due mainly to an 
additive effect of the two drugs on the LDL fractional clearance rate (25), while there 
was a significant but less dramatic impact of combination therapy on VLDL and IDL 
clearance rates. It was noteworthy also that IDL to LDL conversion was decreased by 
PCSK9 inhibition but not by statin therapy and this contributed to the fall in LDL 
apoB in both the mono- and combination- therapy settings (25,26).  
 
Recent clinical trials of combination therapy - statin plus PCSK9 inhibitor (plus 
ezetimibe in some cases) - reveal that, as in the healthy subjects in Figure 1, LDLc in 
patients at very high risk can be reduced routinely to extremely low levels (29-31). 
Further, those with heterozygous familial hypercholesterolemia (FH) in whom LDL 
receptor expression is compromised can achieve normal or even low-normal LDL 
levels as the addition of a PSCK9 inhibitor to statin stimulates maximal expression of 
the remaining functional allele (32). There is, however, emerging evidence that 
statins and PCSK9 inhibitors may have differential effects in certain hyperlipidemic 
states. It is known that in patients with elevated plasma triglyceride levels, statins 
lower VLDL, IDL and LDL to approximately the same degree (20,33); the percent 
reduction in plasma triglyceride in those with levels of this lipid in the 1.5-4.0 
mmol/l range is about the same as the percent decrease in LDLc (33). This is 
attributable to a statin mediated increase in the clearance rate of VLDL that matches 
that of IDL and LDL particles (20) (in distinction to what is seen in 
normotriglyceridemics (Figure 1, 20)). Preliminary analysis of PCSK9 inhibitor trials 
indicates that the decrease in plasma triglyceride (VLDL) is less marked than that of 
LDL in hypertriglyceridemic patients (34). This may point to a preferential action of 
these agents on the clearance pathways of smaller (LDL sized) particles, or an 
additional effect of statins on VLDL catabolism. In terms of determining achieved 
lipid levels, these observations suggest that in hypertriglyceridemic subjects e.g. 
those with obesity or type 2 diabetes, PCSK9 inhibitors may not correct fully the 
atherogenic dyslipidemic profile even when added to statin therapy. The concept 
that a residual risk may be attributed to lipoprotein species in the VLDL density 
range even when achieved LDLc is very low finds support in observations from the 
JUPITER trial - when LDLc was reduced to a mean of 54mg/dl with rosuvastatin, the 
concentration of small VLDL was linked to ongoing risk (35*) – and in an evaluation 
of the effect of evolocumab on lipoprotein particles. Toth et al (36) reported an 
overall decrease in VLDL/ chylomicron particle number of only 15% compared to a 
fall of 44% in LDL. It was noted also that there was a greater effect of the PCSK9 
inhibitor on the larger LDL, and smaller VLDL, sub-species (36). 
  
Lipoprotein (a) comprises an LDL particle to which is covalently bound 
apolipoprotein (a) (apo(a)), a highly variable peptide made up of differing numbers 
of ‘kingle’ subunits. Apo(a) appears to interfere with the affinity of apoB for the LDL 
receptor and thereby alters the clearance route of the particle (15,16). The 
observation that statins failed to decrease circulating Lp(a) levels added to the 
conviction that the LDL receptor was not involved in its catabolism (16). However, 
the finding in clinical trials that PCSK9 inhibitors can reduce Lp(a) by about 25-30% 
has led to a re-evaluation of this concept (29,30,37**). There is evidence from cell 
culture studies that in appropriate conditions Lp(a) has access to the LDL receptor 
pathway and its uptake can be blocked by PCSK9 (37). Also, some human kinetic 
studies have revealed a trend to increased Lp(a) clearance on PCSK9 inhibitor 
therapy (26). So, a current hypothesis is that Lp(a) has a low but not absent affinity 
for the LDL receptor and this clearance pathway becomes active when LDL particle 
numbers are profoundly reduced (Figure 1). PCSK9 inhibition is therefore an 
appropriate therapeutic strategy in high-risk subjects with elevated Lp(a) levels on 
maximal statin treatment (37). 
 
CETP inhibitors are drugs that not only raise HDLc by about two-fold but also lower 
LDLc and Non-HDLc (6,38**). The significant effect on apoB-containing lipoproteins 
was unexpected since variation in the gene for CETP was initially found to be 
associated primarily with change in HDL but not in LDLc or plasma triglyceride (39). 
However, a more comprehensive genomic analysis revealed that some allelic 
variants were linked strongly to reductions in LDLc (40**). CETP mediates the bi-
directional exchange of cholesteryl ester and triglyceride between lipoproteins and 
its usual action is the net transfer of cholesteryl ester from HDL to chylomicrons, 
VLDL and LDL. Hence, when it is blocked almost completely with drugs like 
anacetrapib, HDLc rises dramatically and there is a corresponding decrease in the 
cholesterol content of LDL. It follows that a component of the decrement in achieved 
LDLc with CETP inhibitors is due to compositional change in the lipoprotein. 
However, since plasma apoB falls about 15 to 20% there must also be a decrease in 
number of particles (6,38,40,41). Kinetic studies have attributed the latter to an 
effect on LDL clearance which shows about a 20% increase on anacetrapib (42). 
Since CETP inhibition appears to impact LDL particle abundance in the same manner 
as the other drug classes described above, it is tempting to speculate that it does so 
by reducing cholesterol in a key hepatic regulatory pool. 
 
Mendelian randomization studies of genetic variants that mimic the actions of 
statins, ezetimibe, and PCSK9 inhibitors have been used to demonstrate that 
regardless of the means used to lower LDLc there is a consistency in the impact on 
CHD risk (3); when inherited variation is standardized to a fixed LDLc change e.g. 
10mg/dl, the decrease in risk at 18% is the same for all 3 genetic loci (43). This 
observation extends to CETP inhibition when apoB is used as the measure of lipid 
lowering, change in LDLc at least in those on background statin therapy appears to 
overestimate the risk reduction (40). These seminal genetic observations 
complement the meta-regression analysis that shows that across all lipid lowering 
trials with statins, ezetimibe and PCSK9 inhibitors the decrease in risk per unit 
change in LDLc falls on the same regression line (3,10,43,44). This information is 
highly useful in understanding what has been achieved for a given degree of LDLc 
reduction, and what modifiable residual risk remains. 
 
Composition and measurement of LDL and non-HDL cholesterol on lipid-
lowering therapy. 
 
When receiving a laboratory report of achieved lipid levels, the clinician is faced with the 
questions - ‘Is this the expected response to the prescribed therapy?” and “What more needs 
to be done given the hyperlipidemic- and risk- status of the patient?” It is important 
therefore to interpret the result in light of how the prescribed drugs act, the magnitude of 
the expected change, and any known shortcomings in the assay procedure. This is especially 
the case if the patient is on optimized first-line treatment – usually a statin - and not at goal, 
and a decision has to be made as to whether to proceed to combination or alternate therapy 
(45,46). Further, with the unprecedented ability to drop LDLc to very low levels there needs 
to be greater appreciation of the limitations of current assay techniques.  Laboratory tests 
designed to provide reasonably accurate results in the usual range of values seen in the 
population might not function well when profound lipid lowering is undertaken. There are a 
number of approaches to assessing the concentration of apo-B containing lipoproteins in 
plasma, the most common by far is to measure their cholesterol content, the second, 
arguably more informative, method is to assay apoB itself, and the third is to employ novel 
technologies to determine particle number and size distribution. Accordingly, there are a 
number of factors, described below, that clinicians now need to take into account in 
interpreting results. 
 
Fasting versus non-fasting LDLc estimation 
Classically, lipids have been measured after an overnight fast and the resultant profiles used 
to characterize dyslipidemias and predict risk of CHD. However, recent investigations have 
explored whether fasting is essential to classify an individual’s risk status, and indeed the 
extent to which a non-fasting test provides a superior index of risk (4,11-14).  Recently, the 
European Atherosclerosis Society and the European Federation of Clinical Chemistry and 
Laboratory Medicine concluded in a joint statement that the use of non-fasting samples 
provides an assessment of risk that is at least as robust as that gained from fasting analysis 
(47*). The report highlighted the fact that directly measured LDLc differs little between 
fasted versus non-fasted state, and its estimation from the overall lipid profile (plasma 
cholesterol, triglyceride, HDLc) using approaches such as the Friedewald equation provide 
satisfactory results for the general population (47); calculated LDL from non-fasting subjects 
showed a mean difference of -0.2 mmol/l compared to measured levels. However, other 
investigators addressing this topic have demonstrated systematic bias in Friedewald 
derived LDLc in the non-fasting state (48**), and when LDLc is <1.8 mmol/l (<70mg/dl) 
(48,49)).  A novel calculation has been proposed that adjusts the factor used for the VLDL 
cholesterol: triglyceride ratio (1:5 in the Friedewald calculation) according to the levels of 
Non-HDLc and plasma triglyceride (48). This stratified approach improved the accuracy of 
achieved LDLc estimation, and hence prediction of a patient’s residual risk.  
 
Non-HDL- and remnant- cholesterol estimation. 
Non-HDLc is considered a co-primary target (with LDLc) for lipid-lowering therapy by the 
National Lipid Association of the USA (50), is the primary focus for intervention in UK 
guidelines (51), and is an important subsidiary target in the joint European guidelines (2). 
This lipid fraction as noted above incorporates all apoB-containing lipoprotein species and is 
a convenient alternative to total plasma apoB measurement.  
 
There is no universal agreement of the definition of remnant cholesterol. Some investigators 
view this fraction as ‘total measured cholesterol minus measured HDLc minus estimated 
LDLc’ i.e. all the cholesterol present in the VLDL (plus chylomicron) density ranges (4,11). 
An alternative conceptual definition is that remnant cholesterol is present in in a subfraction 
of partially-lipolysed triglyceride-rich lipoproteins that have a relatively long residence time 
(52). It is difficult to assess the cholesterol component of the latter since the metabolic 
characteristics of the particles do not translate easily into structural variations that would 
allow their separate measurement. Possibly, the closest corollary is the assay for remnant-
like particle (RLP) cholesterol that is based on variation in apoB conformation and 
apolipoprotein content (4). Varbo et al explored whether VLDL cholesterol (Non-HDLc 
minus LDLc) or RLPc gave the better index of risk and found that while both were related to 
CHD in the Copenhagen Heart Study, the former exhibited the stronger relationship (4, 53). 
 
In considering achieved lipid levels and residual risk, for example in patients on statins plus 
PCSK9 inhibitors, it is worthwhile noting changes in the relative contribution of LDLc and 
remnant cholesterol (in this case VLDLc) to the measured Non-HDLc. In Figure 2, based on 
findings reported for the ODYSSEY (29) and OSLER (30) studies, it can be seen that on 
PCSK9 inhibitors remnant cholesterol accounts for a much greater proportion of the 
achieved Non-HDLc due to the greater impact of these agents on LDL versus VLDL 
metabolism (Figure 1). This will be especially true in subjects with elevated plasma 
triglyceride (VLDL) levels such as diabetics and those with combined hyperlipidemia. 
Arguably, therefore, as suggested by expert bodies Non-HDLc should receive as much 
attention as LDLc in devising treatment strategies. 
 
LDLc and high lipoprotein(a) 
It has long been recognized that the cholesterol contained in Lp(a) particles (about 30% of 
the total measured lipoprotein mass) contributes to the observed LDLc level whether the 
latter is estimated (calculated) from the overall lipid profile, or measured directly by 
ultracentrifugation (16). Traditionally, this issue was considered clinically relevant only 
when Lp(a) was high e.g. >50mg/dl total mass. However, with the ability to drive LDL down 
to very low levels using statin plus PCSK9 inhibitors and the differential effect of these drugs 
on LDL and Lp(a) particles (37), there is now a practical problem in that Lp(a) –associated 
cholesterol could be a major component of the measured LDLc, especially when levels are 
below 70mg/dl (54). Statins lower LDLc typically by 25 to 55%, and have little impact on 
Lp(a), or cause a slight increase (16). Ezetimibe lowers LDLc by 20-25% with a modest 
effect on Lp(a) (55) but PCSK9 inhibitors on average reduce LDLc by 60% and Lp(a) by 29%. 
Thus, in the scenarios explored by Yeang et al (54), patients with elevated Lp(a), say 
90mg/dl (27 mg/dl cholesterol) given a PCSK9 inhibitor may exhibit an achieved LDLc of 35 
mg/dl of which only 16mg/dl (i.e. after subtracting 19mg/dl for on-treatment Lp(a)) is ‘true’ 
LDL. Knowledge of Lp(a) will in these circumstances greatly influence interpretation of the 
achieved level. Having said that, there is probably no cause for concern that LDLc has been 
lowered so profoundly since recent investigations exploring potential adverse effects of very 
low LDLc levels have not shown any safety signals even when <25mg/dl, and indeed 
continuing reductions in risk to <10mg/dl (31,56*,57*). 
 Conclusion - Assessing achieved LDLc and Non-HDLc and clinical implications. 
 
With the advent of PCSK9 inhibitors there is now an unprecedented ability to treat patients 
with hypercholesterolemia, especially the inherited condition of familial 
hypercholesterolemia (FH). Clinical trials indicate that LDLc levels in these patients can be 
reduced to goals recommended for the general population and those at high risk with 
established CHD (32,58). The magnitude of the reduction in LDLc appears independent of 
genetic status, and even those with homozygous FH respond as long as they have LDL 
receptors with some functionality (32,59). Since hypercholesterolemic patients will likely 
have elevated levels of VLDL remnants and IDL, and in many cases increased Lp(a) (32), it is 
important to perform a full lipoprotein profile when achieved LDLc is low, <70mg/dl (<1.8 
mmol/l) or Non-HDLc is <100mg/dl, including direct measurement of LDLc, assay of apoB, 
and Lp(a).  
 
Subjects with hypertriglyceridemia will generally respond well to statins (33) with a 
reduction across all apoB-containing lipoproteins (20), and will improve further if given 
ezetimibe and/or PCSK9 inhibitors (29,30). These subjects will have also a preponderance 
of remnants and small, dense LDL in the LDL density range if the plasma triglyceride 
concentration remains above normal (>1.5mmol/l) and on that basis, may have continuing 
high risk of CHD.  
 
At present, there is limited evidence that common genetic variants, or subjects’ 
characteristics such as body weight or age have enough of an impact on the response to 
statins, ezetimibe or PCSK9 inhibitors to influence treatment decisions (1,2). However, it 
should be noted that while the average percent LDLc decrease for a given statin dose and 
potency is reasonably predictable (60) individual responses can vary markedly. One of the 
largest studies to examine this is the JUPITER trial where ‘waterfall’ plots showed LDLc 
change on a fixed dose of 20mg rosuvastatin ranged from a modest increase/no change to 
>80% reduction (61). Similar wide variation was seen in percent change in Non-HDLc and 
apoB. In JUPITER predictors of lower on-treatment LDLc included male sex, Caucasian 
ancestry (61,62), and higher age and body mass index (61). In an exploration of the genetic 
determinants associated with variation in LDLc response to rosuvastatin, 4 loci were 
identified as significant – ABCG2, LPA, APOE and PSCK9 (63), and ranking subjects in groups 
according to the number of alleles linked to lower (baseline) LDLc gave a range of mean 
percent reduction from about 44% to >58%. So, individual gene effects while small in 
magnitude may be important in aggregate in determining not only the LDLc change but also 
clinical benefit. While it is observed in global meta-analysis that the risk reduction per unit 
change in LDLc is relatively consistent regardless of patient type and starting LDLc (64), 
recent studies indicate that subjects with a high cardiovascular gene score (comprised of 
variants linked to increased CHD incidence) experience a greater relative risk reduction for 
a given change in LDLc (65,66). As this information is refined and confirmed, genetic testing 
may indeed in the future form part of the treatment algorithm especially in primary 
prevention.  
 
In summary, the emerging treatment paradigm of profound cholesterol lowering with 
combination therapy affords the clinician a wider range of options when dealing with 
difficult to treat or very high risk patients. Appropriate assessment of what has been 
achieved in terms of decrements in LDLc, Non-HDLc, remnant lipoprotein levels and Lp(a) is 
needed in order proceed with confidence. We still require a more complete picture of the 
effect of PCSK9 inhibitors on the metabolism of VLDL and chylomicrons in order to 
appreciate the full potential of these agents in hypertriglyceridemic states, and the unmet 
need that remains to be addressed by agents still in development (67). 
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Figure legends 
 
Figure 1. Flowchart of apolipoprotein B metabolism in normolipemic subjects on no 
therapy, statin or PCSK9 inhibitor monotherapy and combination therapy (statin 
+PCSK9 inhibitor) 
The schematic depicts VLDL, IDL and LDL particles arranged in a delipidation cascade. The 
VLDL class includes a remnant lipoprotein species (‘R’). Lipoprotein (a) is shown as a 
separate entity; it is derived from the liver but has distinct metabolism in the untreated state 
(No Rx). LDLc is shown as including IDL, LDL and Lp(a). Non-HDLc includes all of the 
particles in LDLc plus cholesterol in VLDL + remnants.  
The illustrative changes in rates/ pool sizes (e.g. 1.2x; 50% decrease) on statin, PCSK9 
inhibitor or on a combination of the two drugs are relative to the basal state (derived from 
references 25, 26). VLDL, IDL and LDL particles are removed from the circulation via the 
action of cell surface receptors, principally the LDL receptor. Statin or PCSK9 inhibitor alone 
increased the clearance rates of LDL, IDL and to some extent VLDL. Combination therapy 
accentuated this action, particularly promoting LDL clearance (25). PCSK9 inhibition 
decreased the conversion of IDL to LDL (25,26). Lp(a) is depicted as being reduced by PCSK9 
inhibition through stimulated clearance by receptors (26,37).  
 
Figure 2.  Response of LDLc and Non-HDLc to PCSK9 inhibitor therapy. 
Change in Non-HDLc, LDLc, plasma triglyceride and remnant cholesterol levels in the 
ODYSSEY Long Term (29) and OSLER (30) studies. ‘Remnant cholesterol’ is this instance was 
the total calculated cholesterol in the VLDL fraction (total plasma cholesterol – HDLc – 
LDLc). 
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